Table 5.
Bisphosphonate use in gastric cancer cases and controls, numbers and odds ratios (95% confidence intervals) compared to non-use by database
| QResearch | CPRD | Combined analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases/controls | Adjusted* odds ratio (95% CI) | P value | Cases/controls | Adjusted* odds ratio (95% CI) | P value | Pooled odds ratio (95% CI) | P value | |||
| Total | 3155/14 715 | — | — | 3157/14 686 | — | — | — | — | ||
| Overall use | ||||||||||
| None | 3014/14 135 | — | — | 3018/13 992 | — | — | — | — | ||
| At least 1 prescription | 141/580 | 1.12 (0.87 to 1.44) | 0.4 | 139/694 | 0.79 (0.62 to 1.01) | 0.06 | 0.93 (0.78 to 1.11) | 0.4 | ||
| Regimen of use | ||||||||||
| Daily | 56/226 | 1.18 (0.84 to 1.67) | 0.3 | 38/247 | 0.60 (0.41 to 0.87) | 0.008 | 0.87 (0.67 to 1.12) | 0.3 | ||
| Weekly or monthly | 85/354 | 1.07 (0.79 to 1.45) | 0.6 | 101/447 | 0.91 (0.69 to 1.19) | 0.5 | 0.98 (0.80 to 1.20) | 0.8 | ||
| Duration of use | ||||||||||
| Short term (<1 year) | 62/195 | 1.37 (0.98 to 1.90) | 0.07 | 60/279 | 0.84 (0.61 to 1.15) | 0.3 | 1.06 (0.84 to 1.33) | 0.6 | ||
| Long term (≥1 year) | 79/385 | 0.96 (0.71 to 1.31) | 0.8 | 79/415 | 0.75 (0.56 to 1.01) | 0.06 | 0.85 (0.68 to 1.05) | 0.1 | ||
| 1-6 months | 33/109 | 1.32 (0.86 to 2.02) | 0.2 | 37/170 | 0.85 (0.58 to 1.26) | 0.4 | 1.04 (0.78 to 1.38) | 0.8 | ||
| 7-36 months | 73/285 | 1.13 (0.83 to 1.53) | 0.4 | 76/332 | 0.90 (0.67 to 1.20) | 0.5 | 1.00 (0.81 to 1.24) | 1.0 | ||
| 37-72 months | 23/131 | 0.83 (0.50 to 1.36) | 0.5 | 20/138 | 0.53 (0.32 to 0.89) | 0.02 | 0.67 (0.47 to 0.95) | 0.03 | ||
| >72 months | 12/55 | 1.23 (0.62 to 2.41) | 0.6 | 6/54 | 0.43 (0.18 to 1.03) | 0.06 | 0.83 (0.49 to 1.41) | 0.5 | ||
| Trend for months of use | — | — | 0.8 | — | — | 0.02 | — | 0.08 | ||
| Alendronate | ||||||||||
| Any use | 102/361 | 1.47 (1.11 to 1.95) | 0.008 | 100/457 | 0.93 (0.71 to 1.22) | 0.6 | 1.16 (0.95 to 1.41) | 0.1 | ||
| <1 year | 59/153 | 1.91 (1.34 to 2.72) | <0.001 | 47/212 | 0.94 (0.66 to 1.34) | 0.7 | 1.34 (1.05 to 1.73) | 0.02 | ||
| ≥1 year | 43/208 | 1.08 (0.74 to 1.59) | 0.7 | 53/245 | 0.93 (0.66 to 1.31) | 0.7 | 0.99 (0.77 to 1.28) | 1.0 | ||
| Trend for months of use | — | — | 0.6 | — | — | 0.1 | — | 0.5 | ||
| Etidronate | ||||||||||
| Any use | 49/222 | 0.93 (0.65 to 1.32) | 0.7 | 31/212 | 0.59 (0.39 to 0.88) | 0.01 | 0.76 (0.58 to 0.99) | 0.05 | ||
| <1 year | 26/87 | 1.20 (0.75 to 1.94) | 0.4 | 15/97 | 0.62 (0.35 to 1.08) | 0.09 | 0.91 (0.63 to 1.31) | 0.6 | ||
| ≥1 year | 23/135 | 0.76 (0.47 to 1.22) | 0.3 | 16/115 | 0.56 (0.33 to 0.98) | 0.04 | 0.67 (0.47 to 0.96) | 0.03 | ||
| Trend for months of use | — | — | 0.6 | — | — | 0.04 | — | 0.1 | ||
| Risedronate | ||||||||||
| Any use | 29/137 | 0.84 (0.54 to 1.30) | 0.4 | 29/149 | 0.83 (0.54 to 1.27) | 0.4 | 0.83 (0.61 to 1.13) | 0.2 | ||
| <1 year | 16/67 | 0.89 (0.50 to 1.60) | 0.7 | 13/74 | 0.75 (0.41 to 1.38) | 0.4 | 0.82 (0.54 to 1.25) | 0.4 | ||
| ≥1 year | 13/70 | 0.72 (0.39 to 1.35) | 0.3 | 16/75 | 0.91 (0.51 to 1.61) | 0.7 | 0.82 (0.54 to 1.25) | 0.3 | ||
| Trend for months of use | — | — | 0.5 | — | — | 0.7 | — | 0.5 | ||
*Adjusted for body mass index, smoking status, alcohol consumption, ethnicity, rheumatoid arthritis, osteoporosis and fractures, use of other osteoporosis drugs, vitamin D, NSAIDs, corticosteroids, acid lowering drugs, years of data, for family history of gastrointestinal cancer.